Trichloroacetic acid 80% (800mg/1ml) solution
Requires a prescription from a doctor or prescriber
Shortage warning
Current supply issues
High shortage warning
Healthcare professionals should be aware of the potential for delayed onset of angioedema and the distinction between bradykinin- and histamine-mediated cases, as treatment strategies differ significantly and bradykinin-medi…
Affected areas: UK
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 4 · Randomised trials: 13 · 1950–2025
Showing the 50 most relevant studies, sorted by most relevant.
Irma Bernadette S. Sitohang, Lili Legiawati, L. Suseno, et al.
Dermatology Research and Practice, 2021
Lorenzo-Ríos D, Arias Berrios G, Cruz Goytía GI, et al.
2024
Dos Santos VF, de Barros IC, Tomazella VLD, et al.
2025
- Papillomavirus Infections
- Condylomata Acuminata
- Trichloroacetic Acid
Amra Batool, Raheel Tahir, Ammara Bakhtawar, et al.
Pakistan Journal of Health Sciences, 2025
Xanthelasma palpebrarum is a common benign eyelid lesion with multiple treatment options. Objectives: To compare the efficacy and safety of 100% trichloroacetic acid (TCA) versus cryotherapy in its management. Methods: A randomized controlled trial was conducted at the Department of Dermatology, Nishtar Hospital, Multan, from November 2024 to April 2025. Sixty patients with untreated bilateral xanthelasma palpebrarum were enrolled using non-probability consecutive sampling and randomly assigned using a computer-generated simple randomization technique (1:1) to receive either 100% trichloroacetic acid or cryotherapy. Treatment efficacy and adverse effects were evaluated at six weeks using standardized clinical criteria. Data were analyzed using SPSS version 26. A confidence level of 95% was used for all statistical analyses. Results were considered statistically significant at a p-value≤0.05. Results: A total of 60 patients (30 patients in each group) with xanthelasma palpebrarum were enrolled, with a mean age of 40.10 ± 7.40 years and a mean disease duration of 11.18 ± 2.94 months. Females comprised 60.0% of the sample, and 63.3% were aged 36–55 years. Excellent treatment response was observed in 53.3% of patients treated with 100% TCA and 20.0% with cryotherapy (p=0.023). Hyperpigmentation (p=0.020) and scarring (p=0.010) were significantly higher in the TCA group. Age, gender, and lesion location showed no significant association with efficacy or adverse effects. Conclusions: TCA offers superior clinical efficacy compared to cryotherapy but with a higher risk of adverse cosmetic effects, underscoring the need for individualized treatment planning in xanthelasma management.
Abstract licence: CC BY 4.0
R. B. Namasivaya Navin, K. Gowthame, Balaji Dhanasekaran, et al.
The Egyptian Journal of Otolaryngology, 2023
Abstract Background The tympanic membrane (TM) forms the partition between the external auditory canal and the middle ear. Perforations occur as a result of acute otitis media or traumatic causes which undergoes healing spontaneously over 3 to 4 weeks. Non-surgical methods are successful in the closure of small to medium-sized perforations. Chemicals used for the cauterization of the margins of perforation are trichloroacetic acid and silver nitrate. This study was performed in a total of 90 patients. External auditory canal, tympanic membrane, site and size of perforation, and middle ear mucosa status were assessed followed by pure tone audiometry. One group constituting 45 subjects underwent TCA cauterization under sterile precautions. Another group of 45 subjects underwent the same procedure with TCA cautery and gel foam application for perforation closure. The procedure was repeated once a week for about 6 weeks. The effectiveness of these two procedures was compared between the two groups after a waiting period of 2 weeks. Results The mean age of the study population is 41.84 ± 16.71. Of the 90 study participants, 54.4% (N = 49) were less than 40 years of age, gender, cause, and laterality of perforation were not associated with the outcome whereas the size of the perforation was significantly associated with the closure of TM perforation with chi-square value of 7.028 and P value of 0.008 (< 0.05). Overall, TM closure was achieved in 3.56 applications in TCA with gel foam patching whereas in 6.02 applications with TCA alone. Conclusion TCA cauterization with or without gel foam patching can be performed as a first-line treatment in adults with small to medium-sized perforations.
Abstract licence: CC BY 4.0
G. Holzer, A. Pinkowicz, S. Radakovic, et al.
British Journal of Dermatology, 2017
Xiaolin Wu, Erhui Xiong, Wei Wang, et al.
Nature Protocols, 2014
- Acetone
- Phenols
- Sodium Dodecyl Sulfate
K. Burton
Biochemical Journal, 1956
- Amines
- Colorimetry
- Diphenylamine
Stanley T. Omaye, John Turnbull, Howerde E. Sauberlich
Methods in enzymology on CD-ROM/Methods in enzymology, 1979
D. B. Zilversmit, A. K. Davis
The Journal of laboratory and clinical medicine, 1950
- Acids
- Blood
- Phospholipids
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.